Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie N Graff

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Drugs & Aging|February 9, 2021
Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older PatientsZizhen Feng, Julie N Graff
Clinical Advances in Hematology & Oncology : H&O|April 17, 2026
Is there an optimal sequential order to androgen receptor axis therapeutics?Jacob Alex, Julie N Graff
Research and Reports in Urology|December 13, 2016
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectivesJia Luo, Julie N Graff
Expert Review of Anticancer Therapy|July 31, 2015
Should docetaxel be administered earlier in prostate cancer therapy?Julie N Graff, Tomasz M Beer
Oncology (Williston Park, N.Y.)|June 21, 2015
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate CancerJulie N Graff, Tomasz M Beer
Drugs & Aging|November 13, 2014
Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agentsJulie N Graff, Tomasz M Beer
Cancer|March 11, 2011
Toward predictors of survival in castration-resistant prostate cancerJulie N Graff, Tomasz M Beer
Cancer|July 3, 2013
The role of C-reactive protein in prostate cancerJulie N Graff, Tomasz M Beer
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|September 10, 2020
Leveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision OncologyJulie N Graff, Grant D Huang
Nature Reviews. Clinical Oncology|January 1, 2016
Metastatic prostate cancer in 2015: The new and the old that is new againJulie N Graff, Tomasz M Beer
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Drugs & Aging|February 9, 2021
Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older PatientsZizhen Feng, Julie N Graff
Clinical Advances in Hematology & Oncology : H&O|April 17, 2026
Is there an optimal sequential order to androgen receptor axis therapeutics?Jacob Alex, Julie N Graff
Research and Reports in Urology|December 13, 2016
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectivesJia Luo, Julie N Graff
Expert Review of Anticancer Therapy|July 31, 2015
Should docetaxel be administered earlier in prostate cancer therapy?Julie N Graff, Tomasz M Beer
Oncology (Williston Park, N.Y.)|June 21, 2015
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate CancerJulie N Graff, Tomasz M Beer
Drugs & Aging|November 13, 2014
Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agentsJulie N Graff, Tomasz M Beer
Cancer|March 11, 2011
Toward predictors of survival in castration-resistant prostate cancerJulie N Graff, Tomasz M Beer
Cancer|July 3, 2013
The role of C-reactive protein in prostate cancerJulie N Graff, Tomasz M Beer
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|September 10, 2020
Leveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision OncologyJulie N Graff, Grant D Huang
Nature Reviews. Clinical Oncology|January 1, 2016
Metastatic prostate cancer in 2015: The new and the old that is new againJulie N Graff, Tomasz M Beer
Pageof 8